Ocugen rises after finishing patient dosing in late-stage eye gene therapy trial

Ocugen

01/04/2026 12:16

** Shares of biotech firm Ocugen OCGN.O rise 2.8% to $1.86 premarket

** Co says it completed enrollment and dosing in a late-stage trial of OCU410ST for Stargardt disease, a rare inherited eye condition that causes gradual vision loss

** Stargardt disease damages the retina — the light‑sensitive tissue at the back of the eye — and currently has no approved treatments

** Co says the trial enrolled 63 patients, including children and adults, in under nine months

** Main goal is to see if the one‑time eye injection can slow disease progression by reducing areas of retinal damage after one year - OCGN

** Co says OCU410ST has shown a favorable safety profile so far, with no serious side effects reported

** As of last close, stock up ~34% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))